Activist Group Launches Full Proxy Contest to Replace Half of Vaxart's Board, Citing Underperformance and Governance Failures
VXRT has more than doubled off its 52-week low of $0.261 on elevated volume (1.8× avg).
Summary
An activist shareholder group is pushing to replace three Vaxart board members, including the CEO, citing years of underperformance, poor capital allocation, and governance issues, ahead of the July 16 annual meeting.
Key Events · Corporate Governance and Compliance · VXRT
-
Proxy Contest Launched
Concerned Vaxart Stockholders are soliciting votes to elect three new directors (Houle, Silverberg, Wallace) to Vaxart's six-member board at the July 16, 2026 annual meeting.
-
Allegations of Underperformance
The activist group highlights a -91% 5-year total shareholder return and -124% vs. S&P Biotech over 10 years, attributing it to board and management failures.
-
Criticism of Dilution and Disclosure
The group points to a June 2024 50M share dilution that allegedly 'erased the entire benefit' of a $453M BARDA award and a failure to disclose a director's FBI investigation.
-
Unresponsive Board on Compensation
The filing notes that 67.5% of stockholders voted against say-on-pay in 2025, yet the board granted larger equity awards, including a 35% YoY increase for the CEO.
Analysis · VXRT · Life Sciences
Concerned Vaxart Stockholders are actively campaigning to replace three incumbent directors, including the CEO, at the upcoming annual meeting. Their detailed investor presentation highlights severe underperformance, alleged value destruction from past dilution, ignored shareholder votes on executive pay, and a failure to disclose a director's FBI investigation. The activist group aims to install new directors with expertise in clinical trials, capital markets, and governance to address these issues and restore shareholder value. This proxy contest represents a significant challenge to the current leadership and could lead to substantial changes in the company's strategic direction and oversight.
At the time of this filing, VXRT was trading at $0.54 on OTC in the Life Sciences sector, with a market capitalization of approximately $129.5M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.